
- Vol 43, Issue 11
Why Depression Subtypes Matter: Lessons From 25 Years in the Clinic
Explore how clinicians subtype depression using severity, stressors, suicidality, sleep, and anxiety patterns to sharpen diagnosis, guide treatment, and build trust.
In my work as a clinical psychiatrist, clinical trialist, and medical educator, I strive for precision in diagnosing depression. In the clinic, accurate diagnosis and syndromal subtyping inform treatment planning and prognosis. In the lab, subtyping reduces heterogeneity across research participants. In the classroom, subtyping organizes complex phenomenology to facilitate learning. Subtyping depression has relevance for patient care, trial design and validity, biomarker discovery, education, training, and communication with patients and other health care providers.
To illustrate how subtyping depression during a clinical evaluation is an active process, I will share how I use deductive and systems-thinking approaches when I am working in the clinic and describe the iterative refining of diagnostic subtypes that occurs during a psychiatric evaluation (
Case Evaluation
In a case where the patient is seeking help for depression (and psychosis, bipolar, and postpartum have been excluded), the next subtype is severity. Symptom burden and associated psychosocial disability are the data used to categorize depression as mild, moderate, or severe. As I practice measurement-based care and obtain a Patient Health Questionnaire-9 (PHQ-9) at every evaluation, this score is integrated with other data related to experience, emotional distress, cognitive effects, and impact on relationships and work. These composite data support a diagnosis of
Similar to anxiety, insomnia is among the most bothersome of depression symptoms, and although not a DSM-5 subtype, prominent sleep symptoms and circadian perturbations should be considered as a clinical subtype because of: (1) the primacy of sleep and circadian health to quality of life, and (2) as a marker of treatment response heterogeneity.
Inquiring about acute and chronic suicidal ideation and behaviors (different from death wish), although not a DSM-5 defined diagnostic subtype, helps refine my understanding of the clinical presentation and level of emotional pain and informs clinical decision-making, treatment, and safety planning. Subtype-specific treatment considerations include prescribing esketamine (the only FDA-approved treatment for patients with MDD and acute suicidality) or escalating the level of care. Considering there are 227 possible ways to meet syndromal criteria for MDD that includes at least 1 of the 2 cardinal symptoms,1 I consider the following additional subtypes to guide medication, psychotherapy, and interventional procedure planning: (1) “anhedonia-dominant” depression, (2) “sadness-dominant” depression, (3) melancholic depression (worse in the morning, predominant neurovegetative symptoms; psychomotor slowing), and (4) atypical depression (rejection sensitivity, fatigue, overeating). This systematic application of deductive reasoning helps determine whether the patient has syndromal depression, a subthreshold depressive disorder, an adjustment disorder or dysthymia, seasonal affective disorder, depression with acute or chronic suicidality, melancholic depression, atypical depression, anxious distress, depression with prominent insomnia/circadian perturbation, and whether the cardinal symptoms are more anhedonia, sadness, or both.
After considering the observed and patient (and family-reported) phenomenology, I next determine whether this is a single (or first) episode of depression, or whether the patient has a recurrent form of the illness. I am also gathering information about the number of medications, psychotherapies, and brain stimulation trials they have tried during this and previous episodes to subtype the presentation as treatment-resistant depression (or my preferred term: difficult-to-treat depression). Subtyping frequency or chronicity of the depression and response to previous trials are data that guide: (1) recommended duration of treatment (ie, does this patient need maintenance pharmacotherapy because they have recurrent depression?), and (2) novel-mechanism treatment approaches. Finally, as I am a geriatric psychiatrist and care for patients with multiple medical problems and neurodegenerative diseases, I subtype the depression phenomenology as possibly related to a medical condition and/or associated with neurodegenerative brain changes.
Concluding Thoughts
In the absence of validated biomarkers to confirm any of these subtypes and guide treatment selection based on biology (except for biomarkers associated with diseases which often present with depression such as Alzheimer disease; uncontrolled endocrine conditions like diabetes, thyroid, or parathyroid disease; some cancers such as pancreatic cancer; assays for drugs of abuse with associated mood symptoms; and diagnosed obstructive sleep apnea), does subtyping depression improve patient outcomes, or is it merely an exercise in deductive reasoning and creating a mental model?
There are a number of reasons why subtyping depression improves outcomes. These include: (1) analysis of safety and risk of self-harm, (2) planning duration of treatment based on frequency or chronicity, (3) selection of suitable psychotherapy, (4) considering fluid, imaging, or polysomnography biomarkers to diagnose or monitor other medical or neurological conditions which may cause or worsen depression or interfere with depression-treatment response, and (5) considering whether novel mechanism treatment approaches should be trialed based on nonresponse or “treatment resistance.” But one of the most important reasons why subtyping depression is important is that it helps patients feel understood and that their doctor has been paying attention.
Eliciting symptoms, feelings, and experiences from a patient and then sharing this summary in the psychiatrist’s own words builds trust and shows that the clinician was listening and is actively using the data to understand the patient’s experience.2 When the summary is accurate, this communication may be a source of comfort and relief for the patient. Patients often experience alexithymia, avoid articulating unpleasant emotions, or are overwhelmed with feelings that they have difficulty putting into words. Accurately describing the patient’s symptoms, experience, and consequences of their depression using language that conveys the depression subtype or primacy of certain symptoms builds rapport and trust. The patient’s engagement in this conversation and provision of feedback to the psychiatrist that their interpretation is accurate or still needs to be refined is an exercise in mutual understanding and relationship-building. When the patient and the psychiatrist agree on the subtype of depression, care planning and identifying goals of treatment follow, often with the patient having increased confidence in their psychiatrist, and the psychiatrist having a clearer path to guide the patient to health.
Dr Karp is professor and chair of the Department of Psychiatry at the
References
1. Zimmerman M, Ellison W, Young D, et al.
2. Ferrara KW. Therapeutic Ways With Words. Oxford University Press; 1994.
Articles in this issue
Related to this article








